8Afschin Gandjour, Karl Wilhelm Lauterbach.Utilitarian Theories Reconsidered: Common Misconceptions, More Recent Developments, and Health Policy Implications [J]. Health Care Analysis, 2003,11 (3) :229-245.
9C A Gericke, A Riesberg,R Busse.Ethical issues in funding orphan drug research and development[J].J Med Ethics,2005,31:164-168.
10Michael F. Drummond, David A. Wilson, Panos Kanavos. Assessing the economic challenges posed by orphan dmgs[J].Intemational Journal of Technology Assessment in Health Care,2007,23( 1 ):36-42.
3Kiran N. Meekings,Cory S.M. Williams,John E. Arrowsmith.Orphan drug development: an economically viable strategy for biopharma R&D[J].Drug Discovery Today (-).2012(13-14)
4Olivier Wellman-Labadie,Youwen Zhou.The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?[J].Health policy.2009(2)
5M.W?STFELT,B.FADEEL,J.‐I.HENTER.A journey of hope: lessons learned from studies on rare diseases and orphan drugs[J].Journal of Internal Medicine.2006(1)
